{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423289,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of front-line, fixed-duration venetoclax and rituximab (VenR) in combination in young (\u226465 years), fit patients with chronic lymphocytic leukemia and unmutated IGHV and\/or TP53 disruption. Treatment consisted of the venetoclax ramp-up, six monthly courses of the VenR combination, followed by six monthly courses of venetoclax as a single agent. A centralized assessment of minimal residual disease (MRD) was performed by allele-specific oligonucleotide polymerase chain reaction assay on the peripheral blood and bone marrow at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range, 38-65), 96% had unmutated IGHV, 12% had TP53 disruption, and 4% had mutated IGHV with TP53 disruption. The overall response rate at the EOT was 94.7%, with a complete remission rate of 76%. MRD was undetectable in the peripheral blood of 69.3% of patients and in the bone marrow of 58.7% of patients. The 12-month MRD-free survival in the 52 patients with undetectable MRD in the peripheral blood at the EOT was 73.1%. After a median follow-up of 20.8 months, no cases of disease progression were observed. Three patients had died, two due to COVID-19 and one due to tumor lysis syndrome. The first report of the VERITAS study shows that front-line VenR was associated with a high rate of complete remissions and durable response with undetectable MRD in young patients with chronic lymphocytic leukemia and unfavorable genetic characteristics. ClinicalTrials.gov identifier: NCT03455517.<\/jats:p>","DOI":"10.3324\/haematol.2022.282116","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T03:12:13Z","timestamp":1673493133000},"page":"2091-2100","source":"Crossref","is-referenced-by-count":7,"title":["High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 \u2013 VERITAS study"],"prefix":"10.3324","volume":"108","author":[{"given":"Francesca R.","family":"Mauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Della","family":"Starza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Orsucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Margiotta","family":"Casaluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Murru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Ilariucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Rigolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Levato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Galieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Belsito","family":"Patrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pietrasanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mattiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Anna","family":"De Novi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stefania","family":"De Propris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"50351","unstructured":"The Surveillance Epidemiology and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Leukemia -Chronic Lymphocytic Leukemia (CLL). 2021. Publisher Full Text|"},{"key":"50352","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Rabe KG, Kay NE. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010; 116(20):4777-4787.","DOI":"10.1002\/cncr.25292"},{"key":"50353","doi-asserted-by":"crossref","unstructured":"Mauro FR, Foa R, Giannarelli D. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999; 94(2):448-454.","DOI":"10.1182\/blood.V94.2.448.414k13_448_454"},{"key":"50354","doi-asserted-by":"crossref","unstructured":"Burger JA, Tedeschi A, Barr PM. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373(25):2425-2437.","DOI":"10.1056\/NEJMoa1509388"},{"key":"50355","doi-asserted-by":"crossref","unstructured":"Burger JA, Barr PM, Robak T. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020; 34(3):787-798.","DOI":"10.1038\/s41375-019-0602-x"},{"key":"50356","doi-asserted-by":"crossref","unstructured":"Woyach JA, Ruppert AS, Heerema NA. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018; 379(26):2517-2528.","DOI":"10.1056\/NEJMoa1812836"},{"key":"50357","doi-asserted-by":"crossref","unstructured":"Woyach JA, Ruppert AS, Heerema NA. Long-term results of Alliance AO41202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood. 2021; 138(Suppl 1):639.","DOI":"10.1182\/blood-2021-153146"},{"key":"50358","doi-asserted-by":"crossref","unstructured":"Moreno C, Greil R, Demirkan F. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022; 107(9):2108-2120.","DOI":"10.3324\/haematol.2021.279012"},{"key":"50359","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Wang XV, Kay NE. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019; 381(5):432-443.","DOI":"10.1056\/NEJMoa1817073"},{"key":"50360","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Wang XV, Hanson CA. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022; 140(2):112-120.","DOI":"10.1182\/blood.2021014960"},{"key":"50361","doi-asserted-by":"crossref","unstructured":"Byrd JC, Brown JR, O\u2019Brien S. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213.","DOI":"10.1056\/NEJMoa1400376"},{"key":"50362","doi-asserted-by":"crossref","unstructured":"Munir T, Brown JR, O\u2019Brien S. Final analysis from RESONATE: up to six years of followDup on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019; 94(12):1353.","DOI":"10.1002\/ajh.25638"},{"key":"50363","doi-asserted-by":"crossref","unstructured":"Ghia P, Pluta A, Wach M. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020; 38(25):2849.","DOI":"10.1200\/JCO.19.03355"},{"key":"50364","doi-asserted-by":"crossref","unstructured":"Sharman JP, Egyed M, Jurczak W. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278.","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"50365","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, Ghia P. First results of a headDtoDhead trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2021; 39(15_suppl):7500.","DOI":"10.1200\/JCO.2021.39.15_suppl.7500"},{"key":"50366","doi-asserted-by":"crossref","unstructured":"Tam CS, Brown JR, Kahl BS. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022; 23(8):1031-1043.","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"50367","doi-asserted-by":"crossref","unstructured":"Tedeschi A, Ferrant E, Flinn IW. Zanubrutinib in combination with venetoclax for patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from arm D of the SEQUOIA (BGB-3111-304) trial. Blood. 2021; 138(Suppl 1):67.","DOI":"10.1182\/blood-2021-144336"},{"key":"50368","unstructured":"Hillmen P, Eichhorst B, Brown JR. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Blood. 2021; 138(Suppl 1):67."},{"key":"50369","doi-asserted-by":"crossref","unstructured":"Mato AR, Shah NN, Jurczak W. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021; 397(10277):892-901.","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"50370","doi-asserted-by":"crossref","unstructured":"Anderson MA, Deng J, Seymour JF. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016; 127(25):3215-3224.","DOI":"10.1182\/blood-2016-01-688796"},{"key":"50371","doi-asserted-by":"crossref","unstructured":"Fischer K, Al-Sawaf O, Bahlo J. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019; 380(23):2225-2236.","DOI":"10.1056\/NEJMoa1815281"},{"key":"50372","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Zhang C, Tandon M. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21(9):1188-1200.","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"50373","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Zhang C, Robrecht S. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. HemaSphere. 2022; 6(Suppl 3):49-50.","DOI":"10.1097\/01.HS9.0000843484.72409.00"},{"key":"50374","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst B. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12):1107D1120.","DOI":"10.1056\/NEJMoa1713976"},{"key":"50375","doi-asserted-by":"crossref","unstructured":"Kater AP, Kipps TJ, Eichhorst B. Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) patients (Pts) following fixed-duration venetoclax-rituximab (VenR) therapy (Tx). Blood. 2020; 136(Supp 1):19-21.","DOI":"10.1182\/blood-2020-136109"},{"key":"50376","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF. Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022; 25(8):839-850.","DOI":"10.1182\/blood.2021015014"},{"key":"50377","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"50378","doi-asserted-by":"crossref","unstructured":"Salvi F, Miller MD, Grilli A. A manual of guidelines to score the modified Cumulative Illness Rating Scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008; 56(10):1926-1931.","DOI":"10.1111\/j.1532-5415.2008.01935.x"},{"key":"50379","doi-asserted-by":"crossref","unstructured":"Rosenquist R, Ghia P, Hadzidimitriou A. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017; 31(7):1477-1481.","DOI":"10.1038\/leu.2017.125"},{"key":"50380","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26):1910-1916.","DOI":"10.1056\/NEJM200012283432602"},{"key":"50381","doi-asserted-by":"crossref","unstructured":"Malcikova J, Tausch E, Rossi D. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia -update on methodological approaches and results interpretation. Leukemia. 2018; 32(5):1070-1080.","DOI":"10.1038\/s41375-017-0007-7"},{"key":"50382","doi-asserted-by":"crossref","unstructured":"Howard SC, Jones DP, Pui C-H. Managing tumor lysis syndrome in the era of novel cancer therapies. J Adv Pract Oncol. 2017; 8(7):705-720.","DOI":"10.6004\/jadpro.2017.8.7.4"},{"key":"50383","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. November. 2017. Publisher Full Text|"},{"key":"50384","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Fazi C, Agathangelidis A. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016; 30(4):929-936.","DOI":"10.1038\/leu.2015.313"},{"key":"50385","doi-asserted-by":"crossref","unstructured":"Raponi S, Della Starza I, De Propris MS. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol. 2014; 166(3):360-368.","DOI":"10.1111\/bjh.12887"},{"key":"50386","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Fink AM, Bahlo J, German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016; 17(7):928-942.","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"50387","doi-asserted-by":"crossref","unstructured":"Hillmen P, Pitchford A, Bloor A. The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial. HemaSphere. 2022; 6(Suppl 3):46-47.","DOI":"10.1097\/01.HS9.0000843472.57904.29"},{"key":"50388","doi-asserted-by":"crossref","unstructured":"Wierda WG, Allan JN, Siddiqi T. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021; 39(34):3853-3865.","DOI":"10.1200\/JCO.21.00807"},{"key":"50389","doi-asserted-by":"crossref","unstructured":"Tam CS, Allan JN, Siddiqi T. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022; 139(22):3278-3289.","DOI":"10.1182\/blood.2021014488"},{"key":"50390","doi-asserted-by":"crossref","unstructured":"Tedeschi A, Frustaci AM, Mauro FR. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?. Blood Adv. 2021; 5(24):5490-5500.","DOI":"10.1182\/bloodadvances.2021004824"},{"key":"50391","unstructured":"Eichhorst B, Niemann C, Kater A. Time-limited venetoclax-obinutuzumab +\/- ibrutinib is superior to chemoimmunotherapy in front-line chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA\/CLL13 trial. HemaSphere. 2022; 6(Suppl 3)"},{"key":"50392","doi-asserted-by":"crossref","unstructured":"Munir T, Moreno C, Owen C. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the GLOW study. Blood. 2021; 138(Suppl 1):70.","DOI":"10.1182\/blood-2021-148666"},{"key":"50393","doi-asserted-by":"crossref","unstructured":"Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today. 1994; 15(3):95-97.","DOI":"10.1016\/0167-5699(94)90148-1"},{"key":"50394","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-1847.","DOI":"10.1182\/blood.V94.6.1840.418k06_1840_1847"},{"key":"50395","doi-asserted-by":"crossref","unstructured":"Ibrahim S, Keating M, Do KA. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001; 98(1):181-186.","DOI":"10.1182\/blood.V98.1.181"},{"key":"50396","doi-asserted-by":"crossref","unstructured":"Damle RN, Temburni S, Calissano C. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007; 110(9):3352-3359.","DOI":"10.1182\/blood-2007-04-083832"},{"key":"50397","unstructured":"Sargent RL, Craig FE, Swerdlow SH. Comparison of Bcl-2, CD38 and ZAP-70 expression in chronic lymphocytic leukemia. Int J Clin Exp Pathol. 2009; 2(6):5745-5782."},{"key":"50398","doi-asserted-by":"crossref","unstructured":"Thompson PA, Peterson CB, Strati P. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018; 32(11):2388-2398.","DOI":"10.1038\/s41375-018-0132-y"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282116\/75209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282116\/75876","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10936\/75209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:10Z","timestamp":1794045790000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282116","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}